Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Prospective, Open-label, Multicentre Phase-II-trial to Evaluate the Efficacy and Safety of a Fitness-adapted Therapy Approach With Either Continuous Zanubrutinib (BGB-3111) Monotherapy or Time-limited Zanubrutinib + Sonrotoclax (BGB-11417) in Older (Aged ≥80 Years) and/or Frail Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL)
Authors not listed
German CLL Study Group · 2026
Abstract
The CLL-Frail2 trial will be a prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a fitness-adapted therapy approach with either con-tinuous zanubrutinib (BGB-3111) monotherapy or time-limited zanubrutinib + sonrotoclax (BGB-11417) in older (aged ≥80 years) and/or frail patients with treatment-naïve CLL. The primary objective of the study is to evaluate the efficacy and safety of fitness-adapted therapy in older (aged ≥80 years) and/or frail patients with treatment-naïve CLL.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Anonymous. (2026). A Prospective, Open-label, Multicentre Phase-II-trial to Evaluate the Efficacy and Safety of a Fitness-adapted Therapy Approach With Either Continuous Zanubrutinib (BGB-3111) Monotherapy or Time-limited Zanubrutinib + Sonrotoclax (BGB-11417) in Older (Aged ≥80 Years) and/or Frail Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL). <em>German CLL Study Group</em>. https://clinicaltrials.gov/study/NCT07899398
Vancouver
Anonymous. A Prospective, Open-label, Multicentre Phase-II-trial to Evaluate the Efficacy and Safety of a Fitness-adapted Therapy Approach With Either Continuous Zanubrutinib (BGB-3111) Monotherapy or Time-limited Zanubrutinib + Sonrotoclax (BGB-11417) in Older (Aged ≥80 Years) and/or Frail Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL). German CLL Study Group. 2026.
BibTeX
@misc{anon2026AProsp,
title = {A Prospective, Open-label, Multicentre Phase-II-trial to Evaluate the Efficacy and Safety of a Fitness-adapted Therapy Approach With Either Continuous Zanubrutinib (BGB-3111) Monotherapy or Time-limited Zanubrutinib + Sonrotoclax (BGB-11417) in Older (Aged ≥80 Years) and/or Frail Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL)},
author = {Anonymous},
journal = {German CLL Study Group},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nicola Goekbuget 2018
Open access · US-GOV
Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Followed by Chemotherapy Consolidation and Maintenance Therapy In Patients Aged 56 Years and Older With Acute Lymphoblastic Leukemia (ALL)
Goethe University 2012
Open access · US-GOV
An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Nilotinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)
Cardiff University 2021
Open access · US-GOV
An Open Label, 3-arm, Randomised Phase II Study to Compare the Safety and Efficacy of Ponatinib in Combination With Either Chemotherapy or Blinatumomab With Imatinib Plus Chemotherapy as Front-line Therapy for Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)
Memorial Sloan Kettering Cancer Center 2016
Open access · US-GOV
A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
Gerencia de Atención Primaria, Madrid 2018
Open access · US-GOV
Effectiveness of a Physical Activity Intervention in the Quality of Life of Pre-frail Older Adults Aged 65 Years or Over With Chronic Pain. Randomized Controlled, Multicenter and Pragmatic Trial in Primary Care.
Guangzhou Patronus Biotech Co., Ltd. 2025
Open access · US-GOV